Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2015 on Tuesday, 22 September 2015.
A group analyst briefing will be held at 8:30am on Tuesday, 22 September 2015 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email firstname.lastname@example.org to register.
Clinigen Group plc
Tel: +44 (0) 1283 495010
Peter George, Group Chief Executive Officer
Shaun Chilton, Group Deputy CEO
Robin Sibson, Group Chief Financial Officer
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard (Corporate Broking)
Peel Hunt LLP
Tel: +44 (0) 20 7418 8900
James Steel/Jock Maxwell Macdonald
Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow
Notes to Editors
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen CTS we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen SP, we market our own portfolio of niche commercial products.
We are global leaders in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.
For more information, please visit www.clinigengroup.com.